Malady Kyle 4

What Happened Kyle Malady, EVP and Group CEO—VZ Business, was granted 135.715 shares of phantom stock (reported as a derivative award) on June 4, 2026. The filing lists a per-share value of $12.81, for a total reported value of $1,739. This was an award/grant (code A), not an open-market purchase or sale.

Key Details

• Transaction date and price: 2026-06-04 at $12.81 per phantom share.
• Quantity and value: 135.715 phantom shares; total reported value $1,739.
• Shares owned after transaction: Not specified in this filing.
• Footnotes: F1 — each phantom share is cash-settled and payable upon events chosen under the deferred compensation plan; F2 — amount includes phantom stock acquired via dividend reinvestment.
• Filing timeliness: Report filed 2026-06-05 (one day after the transaction), appearing timely.
• Transaction code: A (award/grant of a derivative/phantom equity instrument).

Context Phantom stock is a cash-settled deferred compensation instrument that tracks the economic value of common shares but does not represent actual stock ownership until settled; payouts occur under plan rules and may be delayed for tax/deferral reasons. Such grants are typically routine compensation for executives and should not be interpreted as an open-market buy or sell signal.